Arkolith/Insider Trading/EVOK/Form 4

D'Onofrio Matthew J

Chief Executive Officer, DirectorEvoke Pharma Inc (EVOK) · full profile →Form 4 · filed Dec 17, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 16, 2025Tender(U)16K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 17, 2025Disposed to issuer(D)65K——0
Dec 17, 2025Disposed to issuer(D)70K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-322637) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML